Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 45(3); 2013 > Article
Original Article Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study
Kyu-Won Jung, MS1, Young-Joo Won, PhD1, Hyun-Joo Kong, MS1, Chang-Mo Oh, MD, PhD1, Aesun Shin, MD, PhD1,2, Jin-Soo Lee, MD, PhD1
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2013;45(3):162-171.
DOI: https://doi.org/10.4143/crt.2013.45.3.162
Published online: September 30, 2013

1The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Korea.

2Molecular Epidemiology Branch, National Cancer Center, Goyang, Korea.

Correspondence: Young-Joo Won, PhD. The Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 410-769, Korea.
Tel: 82-31-920-2015, Fax: 82-31-920-2179, astra67@ncc.re.kr
• Received: July 24, 2013   • Accepted: August 13, 2013

Copyright © 2013 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 17,468 Views
  • 164 Download
  • 100 Crossref
  • 105 Scopus
prev next
Full Article

Download PDF Download PDF

  • Purpose
    Although the cancer stage at diagnosis is the most important prognostic factor for patients' survival, there are few population-based estimates of stage-specific survival outcome, especially in Asian countries. Our study aims to estimate stage-specific survival for Korean patients.
  • Materials and Methods
    We analyzed the Korea National Cancer Incidence Database data on 626,506 adult patients aged ≥ 20 years, who were diagnosed between 2006 and 2010 with stomach, colorectal, liver, lung, breast, cervix, prostate, and thyroid cancers. Patients were followed up to December 2011, and the 5-year relative survival rates (RSRs) were calculated for gender and age group by Surveillance, Epidemiology, and End Results (SEER) stage at diagnosis.
  • Results
    The 5-year RSRs for all localized-stage cancers, except for lung and liver, exceeded 90% with that for thyroid cancer being the highest at 100.4%. These values for distant stage liver, lung, and stomach cancers were very dismal at 2.5%, 4.8%, and 5.5%, respectively, while it was 69.1% for thyroid cancer, and was in the range of 18.3-36.4% for colorectal, cervix, breast and prostate cancers. Overall, the 5-year RSRs for all cancer types decreased with aging across all the disease stages with exception of prostate cancer, which suggests biologic difference in these cancer types in a young age group. When compared with US SEER data, Korean patients had better stage-specific survival rates for stomach, colorectal, liver, and cervical cancers.
  • Conclusion
    Korean cancer patients showed relatively favorable stage distribution and 5-year RSRs, which suggests potential contribution of the national cancer screening program.
  • Key words: Korea, Neoplasms, Survival, Stage, Cancer Registry
Cancer is the leading cause of death in Korea. Over 200,000 new cancer cases are diagnosed annually, and 1 in 4 deaths is caused by cancer [1].
Population-based cancer survival estimates reflect the average prognosis for a given cancer type, as they are based on unselected patients with a variety of natural histories as well as treatment patterns. Although the cancer stage at diagnosis is the most important prognostic factor for patients' survival, there are limited population-based studies of stage-specific survival, especially those in Asian countries [2,3].
The Korea Central Cancer Registry (KCCR) has published national cancer statistics annually, including incidence, mortality, survival, and prevalence, since 2009 [4]. From the data on incidence in 2003, the KCCR collected information regarding the stage at diagnosis using the Surveillance, Epidemiology, and End Results (SEER) summary stage. Summary staging is a basic way of categorizing how far a cancer has spread from its origin. Several cancer registries in the North America report their data by the summary stage, as the staging categories are broad enough to measure the success of cancer control efforts and other epidemiologic efforts [5]. The KCCR has reported the disease stage distribution of incident cases from 2005 to 2010 [6], and it is possible to calculate survival by the stage at diagnosis using this data.
This study aimed at reporting the stage-specific survival rates for the 8 most common cancers diagnosed during the period 2006-2010 in Korea and at comparing the stage-specific survival rates between Korea and the US.
The Korean Ministry of Health and Welfare started a nationwide, hospital-based cancer registry called the KCCR in 1980. Details of the history, objectives, and activities of the KCCR have been documented [7]. The primary cancer was classified according to the International Classification of Diseases for Oncology 3rd edition [8] and converted to the classification system used by the International Classification of Diseases 10th edition [9]. The analysis was restricted to the most frequent 8 cancer sites and to patients aged≥20 years, because childhood cancers differ from adult cancers in many respects. Cases of cancer at the following 8 sites were analyzed: stomach (C16), colorectum (C18-C20), liver (C22), lung (C33-C34), female breast (C50), cervix uteri (C53), prostate (C61), and thyroid (C73). Records were excluded if the diagnosis was established by death certificate only and in cases where the year of birth or death was not known. The survival analysis used 626,506 cancer cases for the selected cancer sites diagnosed during 2006-2010, for whom the vital status of patients was followed up until December 31, 2011. Passive follow-up was conducted using mortality database maintained from the Statistics Korea and population registration database from the Ministry of Security and Public Administration. The duration of survival for each case was determined as the duration from the date of initial diagnosis to the date of death, loss to follow-up, or date of follow-up termination, whichever came first.
Age at diagnosis was classified into 4 groups: 20-49, 50-64, 65-74, and ≥75 years. Stage at diagnosis was classified as localized (invasive cancer confined to the organ of origin), regional (spread to adjacent organs and/or regional lymph nodes by direct extension), distant (extension to organs other than those covered in the regional category or metastases to distant organs or distant lymph nodes), or unknown. The KCCR records constituted the best available information on the stage of disease as it appears in the medical record within 4 months of diagnosis.
Relative survival is a net survival measure representing cancer survival and the absence of other causes of death. Relative survival rates (RSRs) were defined as the ratio of the observed survival rate to the expected rate; this was based on a group of people in the general population similar to the patient group with respect to sex, age, and calendar period of observation [10]. Therefore, the survival experience of the patients was adjusted for the average life expectancy of the general population of the same age, which makes the RSR an estimate of the chance of surviving the effects of cancer. Additionally, a RSR of 100% implies that a cancer patient cohort is just as likely to survive the given interval as a cohort in the general population of the same sex and age; it does not mean that everyone in the group has survived cancer.
The RSRs were calculated using the Ederer II method [11]. Relative survival analyses were based on an algorithm developed in SAS by Paul Dickman, with some minor adaptations. Asymmetric observed survival confidence intervals (CIs) were formed from standard errors estimated using Greenwood's method [12] and log (-log) transformation. All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC).
Table 1 shows the basic characteristics of 626,506 cancer patients with the 8 cancer types selected for this study that were diagnosed in 2006-2010. Cancers of the stomach, colon and rectum, liver, and lung were found to be more frequent in men than in women, whereas higher proportion of thyroid cancer was observed in women (84.2% of thyroid cancers reported). The median age at cancer diagnosis was the oldest in prostate cancer cases (70 years) and the youngest in cases of female breast cancer (49 years). With respect to the stage at diagnosis, the percentage of localized cancer varied from 18.3% to 56.4% by the cancer site. Of the 8 cancer types examined, lung cancer was the most severe with 40.6% of cases defined as distant, compared to only 1% of thyroid cancers. SEER stage was unknown in 9.9-20.2%, which varies by cancer types.
Table 2 shows the 5-year RSRs and 95% CIs for the 8 cancer types by sex, age group, and stage at diagnosis. The overall 5-year RSR was the highest for thyroid cancer (99.8%) and the lowest for lung cancer (19.7%). The 5-year RSRs for stomach, colorectal, liver, and thyroid cancers were similar or higher in men (67.7%, 74.5%, 26.6%, and 99.8%, respectively) compared with women (65.7%, 69.9%, 26.7%, and 99.7%, respectively), whereas those for lung cancer were much higher in women (25.4%) than in men (17.5%).
For most cancer sites, the 5-year survival rates in younger individuals were higher than that for individuals aged ≥75 years. Indeed, the 5-year RSRs for patients aged ≥75 years were lower than that for all other age groups.
There was considerable variation in the distribution of the stage at diagnosis. For stomach, colorectal, female breast, cervix uteri, prostate, and thyroid cancers, the 5-year RSRs for localized stage disease were >90%. Conversely, the 5-year RSRs for liver and lung cancers were 42.8% and 46.3%, respectively. Survival rates for patients with distant stage cancers ranged from 2.5% to 69.1%, with patients with liver cancer showing the lowest and those with thyroid cancer showing the highest RSR. For all 8 cancer sites, the 5-year RSRs for patients with unknown stage at diagnosis were lower than that of the overall RSRs.
Table 3 shows the stage distribution and 5-year RSRs for 5 cancer sites by sex. For stomach, colorectal, and liver cancers, the stage distribution in men and women were similar and survival rates were similar for every stage at diagnosis. In cases of lung cancer, women had a higher proportion of distant stage lung cancer than men, whereas the survival rate for distant stage lung cancer was much higher in women. Among patients with distant stage thyroid cancer, men had poorer stage-specific survival than women.
Table 4 and Fig. 1 present the distribution of stage at diagnosis by age group and the 5-year RSRs for the 8 cancer sites. Diagnosis with localized stage cancer of the stomach, colorectum, liver, breast, cervix uteri, and prostate was more common among younger individuals than among older individuals. There was substantial variation by age group and stage at diagnosis. Survival rates for all the selected cancers except for the prostate cancer showed decreasing trends with age across all stages of disease. In general, younger patients showed better survival than older patients, whereas prostate cancer patients aged 20-49 years had worse survival outcomes than patients aged ≥50 years. However, unknown stage for prostate cancer, patients who were aged ≥75 years had worse survival outcomes than patients aged <75 for all stages of disease.
Table 5 shows the comparison of stage distribution and survival rates of cancer patients from Korea and the US. Korean patients with stomach cancer and cervical cancer are more likely to be diagnosed at early stage of disease and were observed better stage-specific survival than among patients from the US. Conversely, for prostate cancer survival, Koreans are less likely than US patients to be diagnosed with early stage.
The extent of disease at diagnosis is the most important prognostic factor for patients' survival. The 5-year RSR for each stage at diagnosis, except for stomach and prostate cancer, was much higher in younger than in elderly patients, with the differences being greater for stomach, lung, and cervical cancers. Several studies have reported poor survival and the need for different strategies for elderly cancer patients [13-15]. This may be due to the advanced stage at diagnosis or the presence of comorbidities [15,16], as well as difficulty in accessing care or the lack of availability of appropriate care [17].
The 5-year survival rate for Korean patients with stomach cancer during 2006-2010 was 67.0%, whereas that for American patients during 2002-2008 was 26.9% (Table 5). The prognosis for Korean patients was better mainly because of a more favorable stage distribution than that observed for American patients. Approximately 51% of patients with stomach cancer had localized disease, whereas, tumor spread to distant organs or lymph nodes was identified at the time of diagnosis in 34% of cases in the US. However, only 26% and 12% of stomach cancer cases in Korea were classified as having regional and distant metastasis, respectively. The Korean government initiated a nationwide stomach cancer screening program for men and women aged ≥40 years in 1999, which appears to have led to earlier diagnosis and treatment of stomach cancer. According to a recent report from the Korean Gastric Cancer Association [18], the proportion of patients diagnosed with early-stage gastric cancer has markedly increased from 28.6% in 1995 to 57.7% in 2009. Populations with a higher incidence of stomach cancer have better survival rates than those with a lower incidence [19]. In addition, survival of patients with stomach cancer is partly influenced by the tumor location and histological type. Tumors located in the gastric cardia have a much poorer prognosis than non-cardia gastric cancer. Differences in median age, body mass index, lymph node dissection between Korean and US patients also maybe in part explain the different survival rates of gastric cancer at the same stage [20]. The 5-year survival rate for Korean patients with stomach cancer has dramatically increased from 43.0% and 42.6% for men and women, respectively, diagnosed between 1993 and 1995 to 67.7% and 65.7% for men and women, respectively, diagnosed between 2006 and 2010 [1].
For prostate cancer, the 5-year RSRs were 90.2% and 99.2% in Korea and the US, respectively. Further, 82% of prostate cancer cases in the US were localized compared with only 54% of cases in Korea. Analysis of SEER data indicated that the 5-year RSR for prostate cancer patients in the US increased from 83.2% in 1987-1989 to 99.9% in 2001-2007 [21]. Although this improvement partly reflects the increasing proportion of localized or regional prostate cancers diagnosed, stage-specific increases in survival rates have also been observed. The incidence of prostate cancer in Korea increased by 12.8% annually from 1999 to 2010, and an improvement in survival was observed for patients with prostate cancer (from 55.9% in 1993-1995 to 90.2% in 2006-2010) [1]. The results showed that age-specific five-year relative survival was poorer in the age groups 20-49 and ≥75 years, compared to age groups 50-64 and 65-74. Similar trend was also observed in the US. Some studies exhibited the aggressive biologic behavior and rapidly fatal outcome in younger diagnosed with prostate cancer. It is possible that young prostate cancer patients tend to have more advanced disease and histological grade considered because prostate cancer is very rare prior to age 50 and may be diagnosed as a result of symptomatic disease [22].
Similarly, the 5-year RSR for patients with cervix uteri cancer in Korea (80.2%) was much higher than that for patients in the US (67.9%). Regional stage disease is diagnosed less frequently among Korean than US women (25% vs. 36%) and the stage specific 5-year survival rate for Korean (70.9%) than for US (56.7%). Human papillomavirus is considered a necessary cause of cervical cancer, it has been shown that various lifestyle and behavioral aspects, such as reproductive factors, contraceptive use, and smoking, are related factors for cervical cancer risk. Other most important factor, screening reduces advanced stage detection of cervical cancer. Currently, population-based organized cervical cancer screening programs are implemented free of charge all Korean women aged 30 over biennially [23].
For lung cancer, 41% patients in Korea had distant spread at diagnosis. However, complete diagnostic information required for staging was not available in 16% of cases. The stage distribution in men and women was similar, but survival rates were much higher for women, which may be explained by histological differences between genders. Adenocarcinoma was the most common cancer in women, and survival rates among patients with adenocarcinoma was higher than that among patients with squamous cell carcinoma, which was the most common histologic type in men. Smoking and alcohol consumption are predictors of survival in lung cancer [24]. Further, comorbidities could increase the overall mortality among cancer patients.
Overall, survival rates of patients with breast cancer vary by age at diagnosis. The 5-year RSR was 97.6% for localized cancer, and 89.2% for cancer with regional spread. For women diagnosed with regional spread, those aged ≥75 years had a 5-year RSR of 70.3% compared to 89.1% and 83.9% observed in those aged 50-64 years and 65-74 years, respectively. Differences by age group were even greater for cases of distant metastasis.
The 5-year survival rate for patients with thyroid cancer was greater than 99.8%, and the RSRs of patients aged <75 years with localized thyroid cancer or those aged <65 years with regional spread cancer was over 100%. The relative survival estimate of greater than 100% for Korean patients diagnosed with localized thyroid cancers indicates that the observed survival of these cancer patients was actually higher than that of the general population. There are at least 2 possible explanation for this result: it could reflect a selection bias with a higher proportion of people screened from a higher socio-economic group with a lower mortality risk [25], or a diagnosis of thyroid cancer could increase the likelihood that patients undergo medical interventions, which may have a positive impact on their general health and overall survival.
The results of this study should be interpreted with caution. First, the validity of the survival estimates depends on the completeness of cancer registration. In particular, selective under-estimates of patients with a poor prognosis may lead to over-estimation of cancer patient survival. However, the completeness of cancer registration in Korea was reported to be over 97% [1], which is relatively good. Second, validation of stage information is critical for comparing survival rates. Many registries have routinely collected stage-at-diagnosis data using the SEER summary due to the ease of data collection from medical records. Although the SEER stages are not as detailed as those defined by other staging systems, reports indicate that the SEER stage provides an effective adjustment for stage at diagnosis. However, the proportion of unknown stage cases reported in Korea was relatively high, which makes it difficult to compare the survival rate by stage distribution directly for some cancer sites. Third, we used all subjects who are diagnosed from 2006 to 2010 as incident cancers until the closing date of the follow-up in the analysis. This approach is widely practiced in survival analysis by cancer registry. In this approach, those under observation for a variable period of time and having an incomplete follow-up of less than five years are included, apart from the subjects with a complete follow-up of five years. This approach may lead to under-estimation compared to survival under the condition of full follow-up, because survival expectation of newly diagnosed cancer patients will be higher in the case of recent improvement in prognosis.
This study provides the first population-based stage-specific survival analysis for 8 major cancers in Korean adults. Korean cancer patients showed relatively favorable stage distribution and 5-year RSRs, which suggests potential contribution of the national cancer screening program. This information will be useful for clinicians and cancer patients, as well as for policy makers evaluating and planning the national cancer control program.
Acknowledgements
This work was supported by a research grant from the National Cancer Center (No. 1310220), Republic of Korea.

Conflict of interest relevant to this article was not reported.

  • 1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013;45:1–14. PMID: 23613665ArticlePubMedPMCPDF
  • 2. Kwong A, Mang OW, Wong CH, Chau WW, Law SC. Hong Kong Breast Cancer Research GroupBreast cancer in Hong Kong, Southern China: the first population-based analysis of epidemiological characteristics, stage-specific, cancer-specific, and disease-free survival in breast cancer patients: 1997-2001. Ann Surg Oncol. 2011;18:3072–3078. PMID: 21847700ArticlePubMedPMC
  • 3. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11:165–173. PMID: 20005175ArticlePubMed
  • 4. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, et al. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci. 2009;24:995–1003. PMID: 19949651ArticlePubMedPMC
  • 5. Thornton M. Standards for Cancer Registries, Vol. II. Data standards and data dictionary, record layout version 12.1. 15th ed. Springfield: Notrh American Association of Central Cancer Registries; 2010.
  • 6. The Korea Central Cancer Registry, National Cancer CenterAnnual report of cancer statistics in Korea in 2010. Seoul: Ministry of Health and Welfare; 2012.
  • 7. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001: first result using the National Cancer Incidence Database. Cancer Res Treat. 2005;37:325–331. PMID: 19956367ArticlePubMedPMCPDF
  • 8. World Health OrganizationInternational Classification of Disease for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
  • 9. World Health OrganizationManual of the international statistical classification of diseases, injuries, and causes of death. Geneva: World Health Organization; 1992.
  • 10. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer. 1996;78:2004–2010. PMID: 8909323ArticlePubMed
  • 11. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note 10. Bethesda: National Cancer Institute; 1959.
  • 12. Greenwood M. The errors of sampling of the survivorship table, Vol. 33 of reports on public health and medical subjects. London: Her Majesty's Stationery Office; 1926.
  • 13. Brenner H, Arndt V. Recent increase in cancer survival according to age: higher survival in all age groups, but widening age gradient. Cancer Causes Control. 2004;15:903–910. PMID: 15577292ArticlePubMed
  • 14. Goodwin JS, Samet JM, Hunt WC. Determinants of survival in older cancer patients. J Natl Cancer Inst. 1996;88:1031–1038. PMID: 8683633ArticlePubMed
  • 15. Wedding U, Rohrig B, Klippstein A, Pientka L, Hoffken K. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol. 2007;133:945–950. PMID: 17534661ArticlePubMed
  • 16. Yancik R, Wesley MN, Ries LA, Havlik RJ, Long S, Edwards BK, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123–2134. PMID: 9610691ArticlePubMed
  • 17. Quaglia A, Capocaccia R, Micheli A, Carrani E, Vercelli M. A wide difference in cancer survival between middle aged and elderly patients in Europe. Int J Cancer. 2007;120:2196–2201. PMID: 17285582ArticlePubMed
  • 18. Jeong O, Park YK. Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer. 2011;11:69–77. PMID: 22076206ArticlePubMedPMC
  • 19. Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer. 2003;39:1603–1609. PMID: 12855268ArticlePubMed
  • 20. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251:640–646. PMID: 20224369ArticlePubMed
  • 21. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2009. Bethesda: National Cancer Institute; 2012.
  • 22. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer. 2009;115:2863–2871. PMID: 19466697ArticlePubMedPMC
  • 23. Kim Y, Jun JK, Choi KS, Lee HY, Park EC. Overview of the National Cancer screening programme and the cancer screening status in Korea. Asian Pac J Cancer Prev. 2011;12:725–730. PMID: 21627372PubMed
  • 24. Yu GP, Ostroff JS, Zhang ZF, Tang J, Schantz SP. Smoking history and cancer patient survival: a hospital cancer registry study. Cancer Detect Prev. 1997;21:497–509. PMID: 9398990PubMed
  • 25. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid. 2013;23:103–110. PMID: 23043274ArticlePubMedPMC
Fig. 1
Distribution of 5-year relative survival rates by Surveillance, Epidemiology, and End Results (SEER) summary staging and age at diagnosis.
crt-45-162-g001.jpg
Table 1
Basic characteristics of cancer patients
Characteristic Primary site (%)
Stomach Colorectum Liver Lung Female
breast		 Cervix
uteri		 Prostate Thyroid
Total 133,540 (100) 104,986 (100) 71,270 (100) 81,942 (100) 60,964 (100) 18,408 (100) 29,181 (100) 126,515 (100)
Gender
 Male 89,621 (67.1) 65,575 (59.6) 53,577 (75.2) 59,033 (72.0) - - 29,181 (100) 20,005 (15.9)
 Female 43,919 (32.9) 42,411 (40.4) 17,693 (24.8) 22,909 (28.0) 60,964 (100) 18,408 (100) - 106,210 (84.2)
Age at diagnosis (yr)
 20-49 24,360 (18.2) 15,535 (14.8) 13,341 (18.7) 5,499 (6.7) 33,070 (54.3) 8,590 (46.7) 374 (1.3) 74,128 (58.7)
 50-64 46,979 (35.2) 38,649 (36.8) 29,816 (41.8) 23,163 (28.3) 20,617 (33.8) 5,292 (28.8) 6,969 (23.9) 41,080 (32.6)
 65-74 39,792 (29.8) 32,051 (30.5) 18,318 (25.7) 31,139 (38.0) 5,515 (9.1) 2,820 (15.3) 13,821 (47.4) 9,185 (7.3)
 ≥75 22,409 (16.8) 18,751 (17.9) 9,795 (13.7) 22,141 (27.0) 1,762 (2.9) 1,706 (9.3) 8,017 (27.5) 1,822 (1.4)
Median age (yr) 63 64 61 69 49 51 70 47
Stage at diagnosis
 Localized 68,189 (51.1) 36,569 (34.8) 31,064 (43.6) 14,967 (18.3) 31,373 (51.5) 10,385 (56.4) 15,856 (54.3) 54,078 (42.8)
 Regional 34,467 (25.8) 42,053 (40.1) 15,969 (22.4) 20,929 (25.5) 20,928 (34.3) 4,633 (25.2) 5,549 (19.0) 57,827 (45.8)
 Distant 16,152 (12.1) 15,237 (14.5) 9,856 (13.8) 33,225 (40.6) 2,633 (4.3) 1,116 (6.1) 2,633 (9.0) 1,247 (1.0)
 Unknown 14,732 (11.0) 11,127 (10.6) 14,381 (20.2) 12,821 (15.7) 6,030 (9.9) 2,274 (12.4) 5,143 (17.6) 13,063 (10.4)
Table 2
Five-year relative survival rates and 95% confidence intervals (CIs) for selected cancer sites
Characteristic Primary site (%)
Stomach Colorectum Liver Lung Female
breast		 Cervix
uteri		 Prostate Thyroid
Total 67.0 72.7 26.7 19.7 91.0 80.2 90.2 99.8
(66.7-67.4) (72.2-73.1) (26.2-27.1) (19.3-20.1) (90.7-91.4) (79.4-80.9) (89.3-91.1) (99.6-99.9)
Gender
Male 67.7 74.5 26.6 17.5 - - 90.2 99.8
(67.3-68.1) (74.0-75.1) (26.1-27.2) (17.1-17.9) (89.3-91.1) (99.4-100.2)
Female 65.7 69.9 26.7 25.4 91.0 80.2 - 99.7
(65.1-66.3) (69.3-70.6) (25.8-27.6) (24.6-26.2) (90.7-91.4) (79.4-80.9) (99.6-99.9)
Age at diagnosis (yr)
20-49 72.4 78.5 31.3 32.3 92.3 87.2 83.8 100.2
(71.7-73.0) (77.6-79.3) (30.3-32.3) (30.7-33.9) (91.8-92.7) (86.3-88.0) (77.6-88.6) (100.1-100.3)
50-64 75.1 79.5 32.1 28.4 91.4 81.9 92.8 100.3
(74.6-75.7) (79.0-80.1) (31.4-32.9) (27.7-29.2) (90.8-91.9) (80.5-83.3) (91.5-93.9) (100.1-100.5)
65-74 67.4 72.3 21.8 17.8 87.4 74.3 92.6 97.3
(66.7-68.1) (71.5-73.0) (20.9-22.7) (17.2-18.4) (85.9-88.9) (72.0-76.5) (91.4-93.8) (96.3-98.3)
≥75 41.1 52.5 10.2 9.1 72.0 45.8 83.4 80.2
(39.9-42.2) (51.1-53.8) (9.1-11.3) (8.5-9.8) (67.7-76.2) (42.0-49.6) (80.8-85.9) (75.9-84.3)
Stage at diagnosis
Localized 92.4 93.0 42.8 46.3 97.6 91.1 99.2 100.4
(92.0-92.8) (92.4-93.5) (42.0-43.6) (45.2-47.5) (97.3-97.9) (90.3-91.9) (98.0-100.3) (100.3-100.5)
Regional 55.7 78.0 14.5 27.2 89.2 70.9 94.7 100.1
(55.0-56.4) (77.3-78.6) (13.7-15.3) (26.4-28.1) (88.6-89.9) (69.1-72.7) (92.6-96.6) (99.9-100.2)
Distant 5.5 18.3 2.5 4.8 32.2 25.8 36.4 69.1
(5.0-6.0) (17.4-19.2) (2.1-3.0) (4.5-5.2) (29.5-34.9) (22.4-29.3) (33.3-39.5) (65.4-72.6)
Unknown 49.2 63.2 22.4 15.7 89.1 75.1 87.9 98.6
(48.1-50.2) (62.0-64.4) (21.6-23.3) (14.9-16.6) (88.1-90.1) (72.9-77.2) (85.8-89.9) (98.2-99.0)
Table 3
Stage distribution and 5-year relative survival rates with 95% confidence intervals (CIs) for selected cancer sites by sex
Characteristics Primary site
Stomach Colorectum Liver Lung Thyroid
Stage distribution (%)
 Men
  Localized 46,040 (51.4) 22,632 (36.2) 23,288 (43.5) 10,391 (17.6) 7,313 (36.6)
  Regional 23,293 (26.0) 24,759 (39.6) 12,396 (23.1) 16,163 (27.4) 10,220 (51.1)
  Distant 10,857 (12.1) 8,746 (14.0) 7,395 (13.8) 23,383 (39.6) 329 (1.6)
  Unknown 9,431 (10.5) 6,438 (10.3) 10,498 (19.6) 9,096 (15.4) 2,143 (10.7)
 Women
  Localized 22,149 (50.4) 13,937 (32.9) 7,776 (44.0) 4,576 (20.0) 46,765 (44.0)
  Regional 11,174 (25.4) 17,294 (40.8) 3,573 (20.2) 4,766 (20.8) 47,675 (44.9)
  Distant 5,295 (12.1) 6,491 (15.3) 2,461 (13.9) 9,842 (43.0) 918 (0.9)
  Unknown 5,301 (12.1) 4,689 (11.1) 3,883 (21.0) 3,725 (16.3) 10,920 (10.3)
5-year survival rates (95% CI)
 Men
  Localized 93.2 (92.6-93.6) 94.2 (93.4-94.9) 42.8 (41.9-43.8) 41.2 (39.9-42.6) 100.9 (100.1-101.4)
  Regional 55.5 (54.6-56.4) 79.1 (78.3-80.0) 14.3 (13.4-15.2) 24.5 (23.5-25.4) 100.8 (100.2-101.2)
  Distant 5.5 (4.9-6.1) 18.3 (17.1-19.5) 2.3 (1.8-2.8) 3.9 (3.5-4.3) 59.6 (51.8-66.7)
  Unknown 51.3 (50.0-52.6) 66.8 (65.2-68.4) 22.9 (21.9-24.0) 13.4 (12.5-14.4) 98.1 (96.6-99.2)
 Women
  Localized 91.0 (90.3-91.6) 91.1 (90.2-91.9) 42.5 (41.0-44.1) 57.9 (55.8-59.9) 100.3 (100.2-100.5)
  Regional 56.1 (54.8-57.3) 76.3 (75.4-77.3) 15.1 (13.5-16.8) 36.5 (34.6-38.4) 99.9 (99.8-100.1)
  Distant 5.5 (4.7-6.4) 18.3 (17.0-19.6) 3.4 (2.5-4.4) 7.0 (6.3-7.8) 72.5 (68.2-76.3)
  Unknown 45.4 (43.8-47.0) 58.3 (56.5-60.1) 21.0 (19.5-22.7) 21.4 (19.7-23.1) 98.7 (98.3-99.1)
Table 4
Number of patients and 5-year relative survival rates (RSRs) of selected cancer sites by age and stage at diagnosis
Primary Site Stage at diagnosis
Localized
 Regional
 Distant
 Unknown
No. 5-RSR (SE) No. 5-RSR (SE) No. 5-RSR (SE) No. 5-RSR (SE)
Stomach
 20-49 yr 12,299 97.2 (0.2) 6,745 65.9 (0.7) 3,500 4.9 (0.5) 1,816 67.5 (1.2)
 50-64 yr 26,315 96.7 (0.2) 11,720 62.2 (0.6) 5,102 7.6 (0.5) 3,842 64.9 (0.9)
 65-74 yr 20,690 92.2 (0.4) 10,343 53.4 (0.7) 4,493 5.3 (0.5) 4,266 52.8 (1.0)
 ≥75 yr 8,885 71.2 (1.1) 5,659 31.8 (1.1) 3,057 3.1 (0.5) 4,808 22.8 (0.9)
Colorectum
 20-49 yr 5,761 97.8 (0.3) 5,933 82.1 (0.7) 2,366 22.9 (1.2) 1,475 81.7 (1.2)
 50-64 yr 14,546 97.4 (0.3) 15,509 83.2 (0.5) 5,203 22.1 (0.8) 3,391 78.5 (0.9)
 65-74 yr 10,936 92.2 (0.6) 13,377 77.2 (0.6) 4,551 17.6 (0.9) 3,187 63.8 (1.1)
 ≥75 yr 5,326 75.3 (1.4) 7,234 63.5 (1.2) 3,117 8.8 (0.9) 3,074 33.7 (1.3)
Liver
 20-49 yr 5,766 50.7 (0.9) 3,277 16.5 (0.9) 2,037 2.6 (0.5) 2,261 29.9 (1.1)
 50-64 yr 13,942 48.9 (0.6) 6,642 16.5 (0.7) 3,812 3.1 (0.4) 5,420 29.3 (0.7)
 65-74 yr 7,914 35.3 (0.8) 4,044 11.8 (0.8) 2,508 2.0 (0.4) 3,852 18.0 (0.8)
 ≥75 yr 3,442 17.7 (1.2) 2,006 9.2 (1.1) 1,499 1.6 (0.6) 2,848 6.8 (0.8)
Lung
 20-49 yr 1,006 76.6 (1.8) 1,228 48.0 (1.9) 2,666 8.9 (0.8) 599 30.7 (2.3)
 50-64 yr 4,444 64.4 (0.9) 6,551 37.3 (0.8) 9,640 6.8 (0.4) 2,528 25.6 (1.0)
 65-74 yr 5,794 41.4 (1.0) 8,296 24.0 (0.7) 12,432 3.8 (0.3) 4,617 15.1 (0.7)
 ≥75 yr 3,723 20.5 (1.2) 4,854 12.4 (0.8) 8,487 2.6 (0.3) 5,077 8.8 (0.6)
Female breast
 20-49 yr 16,882 97.8 (0.2) 11,734 90.7 (0.4) 1,354 34.9 (2.0) 3,100 92.7 (0.5)
 50-64 yr 10,790 97.8 (0.3) 6,957 89.1 (0.6) 863 32.4 (2.4) 2,007 90.3 (0.8)
 65-74 yr 2,898 96.6 (0.9) 1,734 83.9 (1.6) 291 25.8 (3.8) 592 83.5 (2.1)
 ≥75 yr 803 93.1 (3.0) 503 70.3 (4.1) 125 16.7 (5.9) 331 51.7 (4.4)
Cervix uteri
 20-49 yr 5,567 95.3 (0.4) 1,772 71.6 (1.4) 354 30.3 (3.1) 897 89.6 (1.1)
 50-64 yr 2,787 90.9 (0.8) 1,567 77.4 (1.5) 339 34.2 (3.6) 599 78.0 (1.9)
 65-74 yr 1,415 85.9 (1.5) 823 68.8 (2.2) 187 20.0 (3.6) 395 70.2 (2.9)
 ≥75 yr 616 63.2 (3.5) 471 48.6 (4.1) 236 9.4 (3.8) 383 36.3 (3.6)
Prostate
 20-49 yr 209 94.6 (2.9) 65 84.1 (7.1) 45 26.6 (10.1) 55 86.7 (5.0)
 50-64 yr 3,982 99.5 (0.6) 1,595 94.7 (1.3) 515 37.6 (3.3) 877 93.7 (1.3)
 65-74 yr 7,723 100.9 (0.7) 2,781 97.1 (1.4) 1,185 39.1 (2.3) 2,132 90.0 (1.4)
 ≥75 yr 3,942 95.3 (1.9) 1,108 88.8 (3.7) 888 32.6 (3.1) 2,079 81.4 (2.4)
Thyroid
 20-49 yr 31,637 100.2 (0.1) 34,842 100.3 (0.0) 450 95.9 (1.3) 7,199 100.0 (0.1)
 50-64 yr 18,110 100.7 (0.1) 18,223 100.6 (0.1) 341 74.6 (3.4) 4,406 99.7 (0.3)
 65-74 yr 3,760 101.2 (0.6) 4,078 97.6 (0.8) 279 45.8 (4.4) 1,068 96.5 (1.3)
 ≥75 yr 571 99.4 (3.2) 684 88.8 (3.7) 177 24.5 (5.5) 390 65.1 (4.6)

Values are presented as number of cases (%). SE, standard error.

Table 5
Comparison of 5-year relative survival rates (RSRs) for selected cancers in Korea and the US by stage at diagnosis
Primary site Stage
at diagnosis		 Korea (2006-2010)
 US (2002-2008)a)
Stage
distribution (%)		 5-year
RSR (%)		 Stage
distribution (%)		 5-year
RSR (%)
Stomach Localized 51 92.4 24 62.3
Regional 26 55.7 31 27.7
Distant 12 5.5 34 3.7
Unknown 11 49.2 11 17.9
All stages 100 67.0 100 26.9
Colorectum Localized 35 93.0 39 89.9
Regional 40 78.0 36 69.6
Distant 15 18.3 20 11.9
Unknown 11 63.2 5 33.9
All stages 100 72.7 100 64.3
Liver Localized 44 42.8 40 27.9
Regional 22 14.5 26 9.8
Distant 14 2.5 19 2.2
Unknown 20 22.4 15 5.9
All stages 100 26.7 100 15.2
Lung Localized 18 46.3 15 52.2
Regional 26 27.2 22 25.1
Distant 41 4.8 56 3.7
Unknown 16 15.7 6 7.9
All stages 100 19.7 100 15.9
Breast Localized 52 97.6 60 98.4
Regional 34 89.2 33 83.9
Distant 4 32.2 5 23.8
Unknown 10 89.1 2 50.7
All stages 100 91.0 100 89.0
Cervix Localized 56 91.1 47 90.7
Regional 25 70.9 36 56.7
Distant 6 25.8 12 16.2
Unknown 12 75.1 4 54.8
All stages 100 80.2 100 67.9
Prostate Localized 54 99.2 82 100.0b)
Regional 19 94.7 11 100.0b)
Distant 9 36.4 4 28.8
Unknown 18 87.9 3 71.1
All stages 100 90.2 100 99.2
Thyroid Localized 43 100.4 68 99.9
Regional 46 100.1 25 97.1
Distant 1 69.1 5 53.9
Unknown 10 98.6 2 87.4
All stages 100 99.8 100 97.5

a)Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2009.

Bethesda: National Cancer Institute; 2012 [21], b)Survival truncated if greater than 1.0 (100%).

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Identifying Suitable Patients for Overcoming Androgen Deprivation Monotherapy in De Novo Metastatic Hormone-Sensitive Prostate Cancer
      Donghyun Lee, Bumjin Lim, Tuan Thanh Nguyen, Se Young Choi
      Journal of Personalized Medicine.2024; 14(5): 517.     CrossRef
    • Clinical outcomes of argon plasma coagulation for the treatment of gastric low-grade dysplasia
      Hoyoung Wang, Ji Yong Ahn, Jin Hee Noh, Hee Kyoung Na, Kee Wook Jung, Jeong Hoon Lee, Do Hoon Kim, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
      Gastrointestinal Endoscopy.2024; 100(2): 221.     CrossRef
    • Association between Gastric Cancer and Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Sample Cohort
      Kyeong Min Han, Mi Jung Kwon, Joo-Hee Kim, Ji Hee Kim, Woo Jin Bang, Hyo Geun Choi, Dae Myoung Yoo, Na-Eun Lee, Nan Young Kim, Ho Suk Kang
      Cancers.2024; 16(13): 2291.     CrossRef
    • Impact of Disability Status on Mortality in Patients with Gastric Cancer: A Nationwide Study Focusing on Regional Disparities
      Woo-Ri Lee, Kyu-Tae Han, Mingee Choi, Seojin Park, Woorim Kim
      Healthcare.2023; 11(5): 641.     CrossRef
    • Examining Final-Administered Medication as a Measure of Data Quality: A Comparative Analysis of Death Data with the Central Cancer Registry in Republic of Korea
      Yae Won Tak, Jeong Hyun Han, Yu Jin Park, Do-Hoon Kim, Ji Seon Oh, Yura Lee
      Cancers.2023; 15(13): 3371.     CrossRef
    • Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy — a nationwide cohort study
      Jinyoung Kim, Kyungdo Han, Jin-Hyung Jung, Jeonghoon Ha, Chaiho Jeong, Jun-Young Heu, Se-Won Lee, Jeongmin Lee, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Ki-Hyun Baek
      Frontiers in Endocrinology.2023;[Epub]     CrossRef
    • The Present and Future of Neoadjuvant and Adjuvant Therapy for Locally Advanced Gastric Cancer
      Anna S. Koerner, Ryan H. Moy, Sandra W. Ryeom, Sam S. Yoon
      Cancers.2023; 15(16): 4114.     CrossRef
    • Trends of stomach cancer survival: A systematic review of survival rates from population‐based cancer registration
      Jia Yi Tuo, Jing Hao Bi, Hui Yun Yuan, Yu Fei Jiang, Xiao Wei Ji, Hong Lan Li, Yong Bing Xiang
      Journal of Digestive Diseases.2022; 23(1): 22.     CrossRef
    • Risk of Psoriasis in Postgastrectomy Gastric Cancer Survivors: A Nationwide Population-Based Cohort Study
      Bo Ri Kim, Dong Ho Lee, Hyun Ik Shim, Jee Woo Kim, Sanghyun Park, Cheol Min Shin, Kyungdo Han, Sang Woong Youn
      Annals of Dermatology.2022; 34(3): 191.     CrossRef
    • A novel ferroptosis-related long noncoding RNA signature for relapse free survival prediction in patients with breast cancer
      Yuzhi Wang, Yunfei Xu, Yi Zhang
      Medicine.2022; 101(31): e29573.     CrossRef
    • Patterns of age disparities in colon and lung cancer survival: a systematic narrative literature review
      Sophie Pilleron, Helen Gower, Maryska Janssen-Heijnen, Virginia Claire Signal, Jason K Gurney, Eva JA Morris, Ruth Cunningham, Diana Sarfati
      BMJ Open.2021; 11(3): e044239.     CrossRef
    • Decreasing trends in thyroid cancer incidence in South Korea: What happened in South Korea?
      Chang‐Mo Oh, Jiwon Lim, Yuh Seog Jung, Yeol Kim, Kyu‐Won Jung, Seri Hong, Young‐Joo Won
      Cancer Medicine.2021; 10(12): 4087.     CrossRef
    • Net survival differences of breast cancer between stages at diagnosis and age groups in the east coast region of West Malaysia: a retrospective cohort study
      Tengku Muhammad Hanis, Najib Majdi Yaacob, Suhaily Mohd Hairon, Sarimah Abdullah
      BMJ Open.2021; 11(5): e043642.     CrossRef
    • Improving the Early Diagnosis of Gastric Cancer
      Robert J. Huang, Joo Ha Hwang
      Gastrointestinal Endoscopy Clinics of North America.2021; 31(3): 503.     CrossRef
    • Effect of Pap smear screening on cervical cancer stage at diagnosis: results from the Korean National Cancer Screening Program
      Cam Nhung Bui, Seri Hong, Mina Suh, Jae Kwan Jun, Kyu Won Jung, Myong Cheol Lim, Kui Son Choi
      Journal of Gynecologic Oncology.2021;[Epub]     CrossRef
    • Bacteria-Derived Extracellular Vesicles in Urine as a Novel Biomarker for Gastric Cancer: Integration of Liquid Biopsy and Metagenome Analysis
      Jae-Yong Park, Chil-Sung Kang, Ho-Chan Seo, Jin-Chul Shin, Sung-Min Kym, Young-Soo Park, Tae-Seop Shin, Jae-Gyu Kim, Yoon-Keun Kim
      Cancers.2021; 13(18): 4687.     CrossRef
    • The global status of research in breast cancer liver metastasis: a bibliometric and visualized analysis
      Yanlong Shi, Wei Wei, Li Li, Qian Wei, Fei Jiang, Guozhi Xia, Hongzhu Yu
      Bioengineered.2021; 12(2): 12246.     CrossRef
    • Prostate Cancer Screening Using Prostate-Specific Antigen Tests in a High-Risk Population in China: A Cost-Utility Analysis
      Xiaojian Qin, Dingwei Ye, Chengyuan Gu, Yongqiang Huang, Weijie Gu, Bo Dai, Hailiang Zhang, Yao Zhu, Han Yang, Shuli Qu
      Current Therapeutic Research.2021; 95: 100653.     CrossRef
    • CalliSpheres drug-eluting beads transarterial-chemoembolization in the treatment of liver metastases from breast cancer
      Xu Chang, Peng Sun, Jianxin Zhang, Lin Zhang, Huiyong Wu, Yinfa Xie, Jibing Liu
      Medicine.2021; 100(52): e28407.     CrossRef
    • Diagnostic performance of MR imaging in evaluating prognostic factors in patients with cervical cancer: a meta-analysis
      Meiling Xiao, Bicong Yan, Ying Li, Jingjing Lu, Jinwei Qiang
      European Radiology.2020; 30(3): 1405.     CrossRef
    • Burden of male hardcore smokers and its characteristics among those eligible for lung cancer screening
      Dong Won Park, Ji-Yun Jang, Tai Sun Park, Hyun Lee, Ji-Yong Moon, Sang-Heon Kim, Tae-Hyung Kim, Ho Joo Yoon, Dae Ryong Kang, Jang Won Sohn
      BMC Public Health.2020;[Epub]     CrossRef
    • Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4
      Dong Ha Kim, Sojung Park, HyeongRyul Kim, Yun Jung Choi, Seon Ye Kim, Ki Jung Sung, Young Hoon Sung, Chang-Min Choi, Miyong Yun, Young-Su Yi, Chae Won Lee, Sang-Yeob Kim, Jae Cheol Lee, Jin Kyung Rho
      Cancer Letters.2020; 475: 2.     CrossRef
    • A Survey of Liver Cancer Specialists’ Views on the National Liver Cancer Screening Program in Korea
      Won Sohn, Young-Sun Lee, Jae Geun Lee, Jihyun An, Eun Sun Jang, Dong Ho Lee, Dong Hyun Sinn
      Journal of Liver Cancer.2020; 20(1): 53.     CrossRef
    • Chemokine receptor 4 expression is correlated with the occurrence and prognosis of gastric cancer
      Yang Li, Hong‐Chang Wang, Jin‐Shen Wang, Bo Sun, Le‐Ping Li
      FEBS Open Bio.2020; 10(6): 1149.     CrossRef
    • The Management of Gastric Intestinal Metaplasia in the United States: A Controversial Topic
      Robert J. Huang, Joo Ha Hwang
      Gastroenterology.2020; 159(1): 402.     CrossRef
    • PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
      Yujun Park, Jiwon Koh, Hee Young Na, Yoonjin Kwak, Keun-Wook Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee
      Cancer Research and Treatment.2020; 52(3): 661.     CrossRef
    • Establishment and validation of a novel autophagy-related gene signature for patients with breast cancer
      Jun-Xian Du, Cong Chen, Yi-Hong Luo, Jia-Liang Cai, Cheng-Zhe Cai, Jing Xu, Xiao-Jian Ni, Wei Zhu
      Gene.2020; 762: 144974.     CrossRef
    • The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: a meta-analysis
      H.J. Oh, B.-H. Yoon, Y.-C. Ha, D.-C. Suh, S.-M. Lee, K.-H. Koo, Y.-K. Lee
      Osteoporosis International.2020; 31(2): 267.     CrossRef
    • Aggressive Local Treatment Improves Survival in Stage IV Breast Cancer With Synchronous Metastasis
      Chen-Lu Lian, Li-Yi Guo, Lei Zhang, Jun Wang, Jian Lei, Li Hua, Zhen-Yu He, San-Gang Wu
      Frontiers in Oncology.2020;[Epub]     CrossRef
    • Use of the alkaline phosphatase to prealbumin ratio as an independent predictive factor for the prognosis of gastric cancer
      Yang Li, Jin-Shen Wang, Yun Guo, Tao Zhang, Le-Ping Li
      World Journal of Gastroenterology.2020; 26(44): 6963.     CrossRef
    • One Size Does Not Fit All: Marked Heterogeneity in Incidence of and Survival from Gastric Cancer among Asian American Subgroups
      Robert J. Huang, Nora Sharp, Ruth O. Talamoa, Hanlee P. Ji, Joo Ha Hwang, Latha P. Palaniappan
      Cancer Epidemiology, Biomarkers & Prevention.2020; 29(5): 903.     CrossRef
    • S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
      Choong-kun Lee, Minkyu Jung, Hyo Song Kim, Inkyung Jung, Dong Bok Shin, Seok Yun Kang, Dae Young Zang, Ki Hyang Kim, Moon Hee Lee, Bong-Seog Kim, Kyung Hee Lee, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha
      Cancer Research and Treatment.2019; 51(1): 1.     CrossRef
    • Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification
      Se Young Choi, Jeman Ryu, Dalsan You, Jun Hyuk Hong, Hanjong Ahn, Choung‐Soo Kim
      International Journal of Urology.2019; 26(1): 62.     CrossRef
    • A Chance to Cut Is a Chance to Cure: Endoscopic Submucosal Dissection for Early Gastric Cancer
      Robert J. Huang, Gregory W. Charville, Joo Ha Hwang, Shai Friedland
      Digestive Diseases and Sciences.2019; 64(5): 1129.     CrossRef
    • Increased Risk of Osteoporosis in Gastric Cancer Survivors Compared to General Population Control: A Study with Representative Korean Population
      Su-Min Jeong, Dong Wook Shin, Ji Eun Lee, Sang-Man Jin, Sung Kim
      Cancer Research and Treatment.2019; 51(2): 530.     CrossRef
    • Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea
      Young-Tak Kim, Beatriz Serrano, Jae-Kwan Lee, Hyunju Lee, Shin-Wha Lee, Crystal Freeman, Jin-Kyoung Oh, Laia Alemany, Francesc-Xavier Bosch, Laia Bruni
      Papillomavirus Research.2019; 7: 26.     CrossRef
    • Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
      Min Hwan Kim, Xianglan Zhang, Minkyu Jung, Inkyung Jung, Hyung Soon Park, Seung-Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyunki Kim, Yoon Young Choi, Taeil Son, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung
      Cancer Research and Treatment.2019; 51(2): 819.     CrossRef
    • Comparative Effectiveness of Abdominal versus Laparoscopic Radical Hysterectomy for Cervical Cancer in the Postdissemination Era
      Jin Hee Kim, Kyungjoo Kim, Seo Jin Park, Jung-Yun Lee, Kidong Kim, Myong Cheol Lim, Jae Weon Kim
      Cancer Research and Treatment.2019; 51(2): 788.     CrossRef
    • Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients
      Canchang Cheng, Qicai Wang, Minggu Zhu, Kelong Liu, Zhiqiao Zhang
      Cancer Cell International.2019;[Epub]     CrossRef
    • Prospective cohort study of patients with early gastric cancer to detect prodromal Parkinson disease (EGC-PPD): A study protocol and baseline characteristics
      Chaewon Shin, Han-Kwang Yang, SungHye Park, Hyuk-Joon Lee, Seong-Ho Kong, Yun-Suhk Suh, Yeon-Ju Huh, Yun-Jeong Kim, So-Yong Park, Tae-Beom Ahn, Seok Hwa Lee, Han-Joon Kim, Beomseok Jeon
      Journal of Clinical Neuroscience.2019; 66: 26.     CrossRef
    • Risk of Dementia in Gastric Cancer Survivors Who Underwent Gastrectomy: A Nationwide Study in Korea
      Yoon Jin Choi, Dong Wook Shin, Wooyoung Jang, Dong Ho Lee, Su-Min Jeong, Sanghyun Park, Kyung-do Han, Yong Gyu Park
      Annals of Surgical Oncology.2019; 26(13): 4229.     CrossRef
    • Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer
      Yujun Park, Jiwon Koh, Yoonjin Kwak, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
      Cancer Immunology, Immunotherapy.2019; 68(11): 1779.     CrossRef
    • Increased Risk of Osteoporotic Fracture in Postgastrectomy Gastric Cancer Survivors Compared With Matched Controls: A Nationwide Cohort Study in Korea
      Dong Wook Shin, Beomseok Suh, Hyunsun Lim, Yun-Suhk Suh, Yoon Jin Choi, Su-Min Jeong, Jae Moon Yun, Sun Ok Song, Youngmin Park
      American Journal of Gastroenterology.2019; 114(11): 1735.     CrossRef
    • Function of fibroblast growth factor 2 in gastric cancer occurrence and prognosis
      Yang Li, Xiao‑Bo Guo, Jin Wang, Hong‑Chang Wang, Le‑Ping Li
      Molecular Medicine Reports.2019;[Epub]     CrossRef
    • Primary Care Comprehensiveness Can Reduce Emergency Department Visits and Hospitalization in People with Hypertension in South Korea
      Nak-Jin Sung, Yong-Jun Choi, Jae-Ho Lee
      International Journal of Environmental Research and Public Health.2018; 15(2): 272.     CrossRef
    • Liver cirrhosis and cancer: comparison of mortality
      Wankyo Chung, Changik Jo, Woo Jin Chung, Dong Joon Kim
      Hepatology International.2018; 12(3): 269.     CrossRef
    • Reproduction of Gastric Cancer Prognostic Score by real-time quantitative polymerase chain reaction assay in an independent cohort
      Kyoung-Mee Kim, Jeeyun Lee, Se Hoon Park, You Jeong Heo, Ji Ryun Jang, Seungtae Kim, Joon Oh Park, Won Ki Kang, Dakeun Lee, Sang-Uk Han, Ji Young An, Min Gew Choi, Tae Sung Sohn, Jae Moon Bae, Sung Kim
      Precision and Future Medicine.2018; 2(1): 27.     CrossRef
    • Long-term survival of patients with thyroid cancer according to the methods of tumor detection: A nationwide cohort study in Korea
      Yuh-Seog Jung, Chang-Mo Oh, Yeol Kim, Kyu-Won Jung, Junsun Ryu, Young-Joo Won, Pierlorenzo Pallante
      PLOS ONE.2018; 13(4): e0194743.     CrossRef
    • Factors related to cancer screening behaviors
      Boyoung Choi, Tae Rim Um, Kwang-Soo Lee
      Epidemiology and Health.2018; 40: e2018011.     CrossRef
    • Radiological Report of Pilot Study for the Korean Lung Cancer Screening (K-LUCAS) Project: Feasibility of Implementing Lung Imaging Reporting and Data System
      Ji Won Lee, Hyae Young Kim, Jin Mo Goo, Eun Young Kim, Soo Jung Lee, Tae Jung Kim, Yeol Kim, Juntae Lim
      Korean Journal of Radiology.2018; 19(4): 803.     CrossRef
    • The Disease Burden of Lung Cancer Attributable to Residential Radon Exposure in Korean Homes
      Jong-Hun Kim, Mina Ha
      Journal of Korean Medical Science.2018;[Epub]     CrossRef
    • Lifestyle interventions to alleviate side effects on prostate cancer patients receiving androgen deprivation therapy: a meta-analysis
      Miaofa Ying, Rui Zhao, Deqi Jiang, Shenglong Gu, Mingxing Li
      Japanese Journal of Clinical Oncology.2018; 48(9): 827.     CrossRef
    • Dual Energy Spectral CT Imaging in the assessment of Gastric Cancer and cell proliferation: A Preliminary Study
      Sai-Ming Cheng, Wei Ling, Jiong Zhu, Jian-Rong Xu, Lian-Ming Wu, Hong-Xia Gong
      Scientific Reports.2018;[Epub]     CrossRef
    • Therapeutic role of axillary lymph node dissection in patients with stage IV breast cancer: a population-based analysis
      San-Gang Wu, Feng-Yan Li, Yue Chen, Jia-Yuan Sun, Huan-Xin Lin, Qin Lin, Zhen-Yu He
      Journal of Cancer Research and Clinical Oncology.2017; 143(3): 467.     CrossRef
    • Thyroid Cancer Overdiagnosis Is a Result of Screening Programs in South Korea
      Elizabeth N. Pearce
      Clinical Thyroidology.2017; 29(1): 8.     CrossRef
    • Fecal occult blood test/fecal carcinoembriogenic antigen dual rapid test as a useful tool for colorectal cancer screening
      Maru Kim, Hyung-Jin Kim, In Kyu Lee, Seong-Taek Oh, Kyungja Han
      European Surgery.2017; 49(3): 127.     CrossRef
    • Supervivencia global de pacientes con cáncer en el Instituto Nacional de Cancerología (INC)
      Constanza Pardo, Esther de Vries
      Revista Colombiana de Cancerología.2017; 21(1): 12.     CrossRef
    • Predictive and Prognostic Biomarkers of Respiratory Diseases due to Particulate Matter Exposure
      Hyo Jeong Kim, Min Gi Choi, Moo Kyun Park, Young Rok Seo
      Journal of Cancer Prevention.2017; 22(1): 6.     CrossRef
    • The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis
      San-Gang Wu, Hui Li, Li-Ying Tang, Jia-Yuan Sun, Wen-Wen Zhang, Feng-Yan Li, Yong-Xiong Chen, Zhen-Yu He
      Tumor Biology.2017; 39(6): 101042831770508.     CrossRef
    • Cancer survival in Qidong between 1972 and 2011: A population-based analysis
      Jian-Guo Chen, Jian Zhu, Yong-Hui Zhang, Yi-Xin Zhang, Deng-Fu Yao, Yong-Sheng Chen, Jian-Hua Lu, Lu-Lu Ding, Hai-Zhen Chen, Chao-Yong Zhu, Li-Ping Yang, Yuan-Rong Zhu, Fu-Lin Qiang
      Molecular and Clinical Oncology.2017; 6(6): 944.     CrossRef
    • Influence of Socioeconomic Status, Comorbidity, and Disability on Late-stage Cancer Diagnosis
      Bo Ram Park, So Young Kim, Dong Wook Shin, Hyung Kook Yang, Jong Hyock Park
      Osong Public Health and Research Perspectives.2017; 8(4): 264.     CrossRef
    • Emergency Department Visits Can Be Reduced by Having a Regular Doctor for Adults with Diabetes Mellitus: Secondary Analysis of 2013 Korea Health Panel Data
      Clara Lee, Nak-Jin Sung, Hyeong-Seok Lim, Jae-Ho Lee
      Journal of Korean Medical Science.2017; 32(12): 1921.     CrossRef
    • Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propensity
      Gyeong Eun Min, Hanjong Ahn
      Oncology Letters.2017; 13(6): 4832.     CrossRef
    • The survival benefits of local surgery in stage IV breast cancer are not affected by breast cancer subtypes: a population-based analysis
      San-Gang Wu, Wen-Weng Zhang, Jia-Yuan Sun, Feng-Yan Li, Huan-Xin Lin, Juan Zhou, Zhen-Yu He
      Oncotarget.2017; 8(40): 67851.     CrossRef
    • Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients
      Jiwon Koh, Chan-Young Ock, Jin Won Kim, Soo Kyung Nam, Yoonjin Kwak, Sumi Yun, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Woo Ho Kim, Hye Seung Lee
      Oncotarget.2017; 8(16): 26356.     CrossRef
    • Stomach Cancer Disparity among Korean Americans by Tumor Characteristics: Comparison with Non-Hispanic Whites, Japanese Americans, South Koreans, and Japanese
      Eunjung Lee, Lihua Liu, Juanjuan Zhang, Mariana C. Stern, Afsaneh Barzi, Amie Hwang, Andre E. Kim, Ann S. Hamilton, Anna H. Wu, Dennis Deapen
      Cancer Epidemiology, Biomarkers & Prevention.2017; 26(4): 587.     CrossRef
    • Financial burden on the families of patients with hepatitis B virus-related liver diseases and the role of public health insurance in Yunnan province of China
      Y.H. Che, V. Chongsuvivatwong, L. Li, H. Sriplung, Y.Y. Wang, J. You, S.J. Ma, Y. Yan, R.Y. Zhang, T. Shen, H.M. Chen, S.F. Rao, X.L. Zhang
      Public Health.2016; 130: 13.     CrossRef
    • Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer
      Keun-Wook Lee, Ju Hyun Lee, Jin Won Kim, Ji-Won Kim, Soyeon Ahn, Jee Hyun Kim
      Journal of Cancer Research and Clinical Oncology.2016; 142(3): 687.     CrossRef
    • Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
      Choong-kun Lee, Minkyu Jung, Inkyung Jung, Su Jin Heo, Yong Hyu Jeong, Ji Yeong An, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung
      Annals of Surgery.2016; 263(1): 96.     CrossRef
    • DNA methylation in human papillomavirus-infected cervical cells is elevated in high-grade squamous intraepithelial lesions and cancer
      Mi-Kyung Kim, In-Ho Lee, Ki-Heon Lee, Yoo Kyung Lee, Kyeong A So, Sung Ran Hong, Chang-Sun Hwang, Mee-Kyung Kee, Jee Eun Rhee, Chun Kang, Soo Young Hur, Jong Sup Park, Tae-Jin Kim
      Journal of Gynecologic Oncology.2016;[Epub]     CrossRef
    • Metastatic Thyroid Gland Tumor Presenting as an Initial Manifestation of Recurrent Uterine Cervical Cancer
      So Dam Hong, Jae Kyoung Shin, Hee Jin Hong, Jin Hyung Heo, So Young Chong, Doyoun Oh, Jisu Oh
      The Korean Journal of Medicine.2016; 90(1): 68.     CrossRef
    • Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study
      Cadeyrn J. Gaskin, Steve F. Fraser, Patrick J. Owen, Melinda Craike, Liliana Orellana, Patricia M. Livingston
      Journal of Cancer Survivorship.2016; 10(6): 972.     CrossRef
    • Aberrant methylation ofPCDH10andRASSF1Agenes in blood samples for non-invasive diagnosis and prognostic assessment of gastric cancer
      Charinya Pimson, Tipaya Ekalaksananan, Chamsai Pientong, Supannee Promthet, Nuntiput Putthanachote, Krittika Suwanrungruang, Surapon Wiangnon
      PeerJ.2016; 4: e2112.     CrossRef
    • Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed
      Sojung Park, Hyun Jung Kim, Chang–Min Choi, Dae Ho Lee, Sang–We Kim, Jung–Shin Lee, Woo Sung Kim, Se Hoon Choi, Jin Kyung Rho, Jae Cheol Lee
      BMC Cancer.2016;[Epub]     CrossRef
    • Changing Patterns of Primary Treatment in Korean Men with Prostate Cancer Over 10 Years: A Nationwide Population Based Study
      Jinsung Park, Beomseok Suh, Dong Wook Shin, Jun Hyuk Hong, Hanjong Ahn
      Cancer Research and Treatment.2016; 48(3): 899.     CrossRef
    • Cause of Death in Korean Men with Prostate Cancer: an Analysis of Time Trends in a Nationwide Cohort
      Jinsung Park, Beomseok Suh, Dong Wook Shin, Jun Hyuk Hong, Hanjong Ahn
      Journal of Korean Medical Science.2016; 31(11): 1802.     CrossRef
    • Does the interval of screening endoscopy affect survival in gastric cancer patients?
      Jieun Kim, Su Mi Kim, Man Ho Ha, Jeong Eun Seo, Min-Gew Choi, Jun Ho Lee, Tae Sung Sohn, Sung Kim, Sin-Ho Jung, Jae Moon Bae
      Medicine.2016; 95(49): e5490.     CrossRef
    • Gastric cancer survival and affiliation to health insurance in a middle-income setting
      Esther de Vries, Claudia Uribe, Constanza Pardo, Valery Lemmens, Ellen Van de Poel, David Forman
      Cancer Epidemiology.2015; 39(1): 91.     CrossRef
    • Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the National Cancer Screening Programme in Korea
      K S Choi, J K Jun, M Suh, B Park, D K Noh, S H Song, K W Jung, H-Y Lee, I J Choi, E-C Park
      British Journal of Cancer.2015; 112(3): 608.     CrossRef
    • A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
      Jin Won Kim, In Sil Choi, Yu Jung Kim, Kyung-Hun Lee, Keun-Wook Lee, Tae-Yong Kim, Sae-Won Han, Jee Hyun Kim, Tae-You Kim, Jong Seok Lee, Yung-Jue Bang, Seock-Ah Im, Do-Youn Oh
      Cancer Chemotherapy and Pharmacology.2015; 75(6): 1175.     CrossRef
    • The Korean guideline for lung cancer screening
      Seung Hun Jang, Seungsoo Sheen, Hyae Young Kim, Hyeon Woo Yim, Bo Young Park, Jae Woo Kim, In Kyu Park, Young Whan Kim, Kye Young Lee, Kyung Soo Lee, Jong Mog Lee, Bin Hwangbo, Sang Hyun Paik, Jin-Hwan Kim, Nak Jin Sung, Sang-hyun Lee, Seung-sik Hwang, So
      Journal of the Korean Medical Association.2015; 58(4): 291.     CrossRef
    • The Korean guideline for gastric cancer screening
      Hyun Ah Park, Su Youn Nam, Sang Kil Lee, Sang Gyun Kim, Ki-Nam Shim, Sang Min Park, Sun-Young Lee, Hye Seung Han, Yong Moon Shin, Kyoung-Mee Kim, Kyung-Jae Lee, Tae-Yong Lee, Il Ju Choi, Seong Sook Hong, Jae Woo Kim, Yoon Jae Lee, Soo Young Kim, Yeol Kim,
      Journal of the Korean Medical Association.2015; 58(5): 373.     CrossRef
    • The Basic Facts of Korean Breast Cancer in 2012: Results from a Nationwide Survey and Breast Cancer Registry Database
      Zisun Kim, Sun Young Min, Chan Seok Yoon, Kyu-Won Jung, Beom Seok Ko, Eunyoung Kang, Seok Jin Nam, Seokwon Lee, Min Hee Hur
      Journal of Breast Cancer.2015; 18(2): 103.     CrossRef
    • Management of gastric cancer: East vs west
      Sook Ryun Park
      Current Problems in Cancer.2015; 39(6): 315.     CrossRef
    • Correlation between Serum 1,25-Dihydroxyvitamin D Levels and Breast Cancer Prognosis in Korea
      Hae Won Bang, Seung Taek Lim, Ye Won Jeon, Young Jin Suh
      Journal of Breast Disease.2015; 3(2): 37.     CrossRef
    • Prognosis of Cervical Cancer in the Era of Concurrent Chemoradiation from National Database in Korea: A Comparison between Squamous Cell Carcinoma and Adenocarcinoma
      Jung-Yun Lee, Young Tae Kim, Sunghoon Kim, Boram Lee, Myong Cheol Lim, Jae-Weon Kim, Young-Joo Won, Jose G. Trevino
      PLOS ONE.2015; 10(12): e0144887.     CrossRef
    • Health Behaviors of Breast Cancer Survivors with Hypertension: A Propensity Analysis of KNHANES III-V (2005-2012)
      Ju-Ri Jeong, Sun Kim, So-Ra Jo, Ju-Youn Joh, Yeon-Pyo Kim, Yinglin Xia
      PLOS ONE.2015; 10(5): e0127346.     CrossRef
    • The Basic Facts of Korean Breast Cancer in 2011: Results of a Nationwide Survey and Breast Cancer Registry Database
      Zisun Kim, Sun Young Min, Chan Seok Yoon, Hun Jae Lee, Jung Sun Lee, Hyun Jo Youn, Heung Kyu Park, Dong-Young Noh, Min Hee Hur
      Journal of Breast Cancer.2014; 17(2): 99.     CrossRef
    • Preoperative MRI criteria for trials on less radical surgery in Stage IB1 cervical cancer
      Jung-Yun Lee, Jina Youm, Tae Hun Kim, Jeong Yeon Cho, Min A Kim, Dong Hoon Suh, Myong Cheol Lim, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
      Gynecologic Oncology.2014; 134(1): 47.     CrossRef
    • A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
      Hee Kyung Ahn, Minkyu Jung, Sun Jin Sym, Dong Bok Shin, Shin Myung Kang, Sun Young Kyung, Jeong-Woong Park, Sung Hwan Jeong, Eun Kyung Cho
      Cancer Chemotherapy and Pharmacology.2014; 74(2): 277.     CrossRef
    • Lung Cancer Screening
      Young-Woong Won
      Hanyang Medical Reviews.2014; 34(1): 15.     CrossRef
    • Reply on "Characteristics and Survival of Korean Anal Cancer From the Korea Central Cancer Registry Data"
      Hyoung-Chul Park, Bong Hwa Lee
      Annals of Coloproctology.2014; 30(1): 56.     CrossRef
    • A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
      Y-K Kang, S Y Rha, P Tassone, J Barriuso, R Yu, T Szado, A Garg, Y-J Bang
      British Journal of Cancer.2014; 111(4): 660.     CrossRef
    • Gender-specific Colorectal Cancer: Epidemiologic Difference and Role of Estrogen
      Hee Man Kim, Hyun-Soo Kim
      The Korean Journal of Gastroenterology.2014; 63(4): 201.     CrossRef
    • Cancer Control Programs in East Asia: Evidence From the International Literature
      Malcolm A. Moore
      Journal of Preventive Medicine & Public Health.2014; 47(4): 183.     CrossRef
    • Abiraterone acetate and prednisolone for metastatic castration‐resistant prostate cancer failing androgen deprivation and docetaxel‐based chemotherapy: A phase II bridging study in Korean and Taiwanese patients
      Cheol Kwak, Tony Tong Lin Wu, Hyun Moo Lee, Hsi Chin Wu, Sung Joon Hong, Yen Chuan Ou, Seok Soo Byun, Hyou Young Rhim, Thian Kheoh, Ying Wan, Howard Yeh, Margaret K Yu, Choung Soo Kim
      International Journal of Urology.2014; 21(12): 1239.     CrossRef
    • Stereotactic Body Radiation Therapy for Prostate Cancer Patients with Old Age or Medical Comorbidity
      Sea-Won Lee, Hong Seok Jang, Jong Hoon Lee, Sung Hwan Kim, Sei Chul Yoon
      Medicine.2014; 93(28): e290.     CrossRef
    • Economic Evaluation of Prostate Cancer Screening Test as a National Cancer Screening Program in South Korea
      Sangjin Shin, Youn Hee Kim, Jin Sub Hwang, Yoon Jae Lee, Sang Moo Lee, Jeonghoon Ahn
      Asian Pacific Journal of Cancer Prevention.2014; 15(8): 3383.     CrossRef
    • Reconsideration of Clinical and Histopathological Prognostic Factors in Breast Cancer Patients: A Single Center Experience
      Ozgur Tanriverdi, Nezih Meydan, Sabri Barutca
      Asian Pacific Journal of Cancer Prevention.2014; 15(2): 807.     CrossRef
    • Differences in the Survival of Gastric Cancer Patients after Gastrectomy according to the Medical Insurance Status
      Jae Seong Jang, Dong Gue Shin, Hye Min Cho, Yujin Kwon, Dong Hui Cho, Kyung Bok Lee, Sang Soo Park, Jin Yoon, Yong Seog Jang, Il Myung Kim
      Journal of Gastric Cancer.2013; 13(4): 247.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study
      Cancer Res Treat. 2013;45(3):162-171.   Published online September 30, 2013
      DOI: https://doi.org/10.4143/crt.2013.45.3.162
      Close
    • XML DownloadXML Download
    • 0
    Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study
    Image
    Fig. 1 Distribution of 5-year relative survival rates by Surveillance, Epidemiology, and End Results (SEER) summary staging and age at diagnosis.

    Fig. 1

    Survival of Korean Adult Cancer Patients by Stage at Diagnosis, 2006-2010: National Cancer Registry Study
    Characteristic Primary site (%)
    Stomach Colorectum Liver Lung Female
    breast    		 Cervix
    uteri    		 Prostate Thyroid
    Total 133,540 (100) 104,986 (100) 71,270 (100) 81,942 (100) 60,964 (100) 18,408 (100) 29,181 (100) 126,515 (100)
    Gender
     Male 89,621 (67.1) 65,575 (59.6) 53,577 (75.2) 59,033 (72.0) - - 29,181 (100) 20,005 (15.9)
     Female 43,919 (32.9) 42,411 (40.4) 17,693 (24.8) 22,909 (28.0) 60,964 (100) 18,408 (100) - 106,210 (84.2)
    Age at diagnosis (yr)
     20-49 24,360 (18.2) 15,535 (14.8) 13,341 (18.7) 5,499 (6.7) 33,070 (54.3) 8,590 (46.7) 374 (1.3) 74,128 (58.7)
     50-64 46,979 (35.2) 38,649 (36.8) 29,816 (41.8) 23,163 (28.3) 20,617 (33.8) 5,292 (28.8) 6,969 (23.9) 41,080 (32.6)
     65-74 39,792 (29.8) 32,051 (30.5) 18,318 (25.7) 31,139 (38.0) 5,515 (9.1) 2,820 (15.3) 13,821 (47.4) 9,185 (7.3)
     ≥75 22,409 (16.8) 18,751 (17.9) 9,795 (13.7) 22,141 (27.0) 1,762 (2.9) 1,706 (9.3) 8,017 (27.5) 1,822 (1.4)
    Median age (yr) 63 64 61 69 49 51 70 47
    Stage at diagnosis
     Localized 68,189 (51.1) 36,569 (34.8) 31,064 (43.6) 14,967 (18.3) 31,373 (51.5) 10,385 (56.4) 15,856 (54.3) 54,078 (42.8)
     Regional 34,467 (25.8) 42,053 (40.1) 15,969 (22.4) 20,929 (25.5) 20,928 (34.3) 4,633 (25.2) 5,549 (19.0) 57,827 (45.8)
     Distant 16,152 (12.1) 15,237 (14.5) 9,856 (13.8) 33,225 (40.6) 2,633 (4.3) 1,116 (6.1) 2,633 (9.0) 1,247 (1.0)
     Unknown 14,732 (11.0) 11,127 (10.6) 14,381 (20.2) 12,821 (15.7) 6,030 (9.9) 2,274 (12.4) 5,143 (17.6) 13,063 (10.4)
    Characteristic Primary site (%)
    Stomach Colorectum Liver Lung Female
    breast    		 Cervix
    uteri    		 Prostate Thyroid
    Total 67.0 72.7 26.7 19.7 91.0 80.2 90.2 99.8
    (66.7-67.4) (72.2-73.1) (26.2-27.1) (19.3-20.1) (90.7-91.4) (79.4-80.9) (89.3-91.1) (99.6-99.9)
    Gender
    Male 67.7 74.5 26.6 17.5 - - 90.2 99.8
    (67.3-68.1) (74.0-75.1) (26.1-27.2) (17.1-17.9) (89.3-91.1) (99.4-100.2)
    Female 65.7 69.9 26.7 25.4 91.0 80.2 - 99.7
    (65.1-66.3) (69.3-70.6) (25.8-27.6) (24.6-26.2) (90.7-91.4) (79.4-80.9) (99.6-99.9)
    Age at diagnosis (yr)
    20-49 72.4 78.5 31.3 32.3 92.3 87.2 83.8 100.2
    (71.7-73.0) (77.6-79.3) (30.3-32.3) (30.7-33.9) (91.8-92.7) (86.3-88.0) (77.6-88.6) (100.1-100.3)
    50-64 75.1 79.5 32.1 28.4 91.4 81.9 92.8 100.3
    (74.6-75.7) (79.0-80.1) (31.4-32.9) (27.7-29.2) (90.8-91.9) (80.5-83.3) (91.5-93.9) (100.1-100.5)
    65-74 67.4 72.3 21.8 17.8 87.4 74.3 92.6 97.3
    (66.7-68.1) (71.5-73.0) (20.9-22.7) (17.2-18.4) (85.9-88.9) (72.0-76.5) (91.4-93.8) (96.3-98.3)
    ≥75 41.1 52.5 10.2 9.1 72.0 45.8 83.4 80.2
    (39.9-42.2) (51.1-53.8) (9.1-11.3) (8.5-9.8) (67.7-76.2) (42.0-49.6) (80.8-85.9) (75.9-84.3)
    Stage at diagnosis
    Localized 92.4 93.0 42.8 46.3 97.6 91.1 99.2 100.4
    (92.0-92.8) (92.4-93.5) (42.0-43.6) (45.2-47.5) (97.3-97.9) (90.3-91.9) (98.0-100.3) (100.3-100.5)
    Regional 55.7 78.0 14.5 27.2 89.2 70.9 94.7 100.1
    (55.0-56.4) (77.3-78.6) (13.7-15.3) (26.4-28.1) (88.6-89.9) (69.1-72.7) (92.6-96.6) (99.9-100.2)
    Distant 5.5 18.3 2.5 4.8 32.2 25.8 36.4 69.1
    (5.0-6.0) (17.4-19.2) (2.1-3.0) (4.5-5.2) (29.5-34.9) (22.4-29.3) (33.3-39.5) (65.4-72.6)
    Unknown 49.2 63.2 22.4 15.7 89.1 75.1 87.9 98.6
    (48.1-50.2) (62.0-64.4) (21.6-23.3) (14.9-16.6) (88.1-90.1) (72.9-77.2) (85.8-89.9) (98.2-99.0)
    Characteristics Primary site
    Stomach Colorectum Liver Lung Thyroid
    Stage distribution (%)
     Men
      Localized 46,040 (51.4) 22,632 (36.2) 23,288 (43.5) 10,391 (17.6) 7,313 (36.6)
      Regional 23,293 (26.0) 24,759 (39.6) 12,396 (23.1) 16,163 (27.4) 10,220 (51.1)
      Distant 10,857 (12.1) 8,746 (14.0) 7,395 (13.8) 23,383 (39.6) 329 (1.6)
      Unknown 9,431 (10.5) 6,438 (10.3) 10,498 (19.6) 9,096 (15.4) 2,143 (10.7)
     Women
      Localized 22,149 (50.4) 13,937 (32.9) 7,776 (44.0) 4,576 (20.0) 46,765 (44.0)
      Regional 11,174 (25.4) 17,294 (40.8) 3,573 (20.2) 4,766 (20.8) 47,675 (44.9)
      Distant 5,295 (12.1) 6,491 (15.3) 2,461 (13.9) 9,842 (43.0) 918 (0.9)
      Unknown 5,301 (12.1) 4,689 (11.1) 3,883 (21.0) 3,725 (16.3) 10,920 (10.3)
    5-year survival rates (95% CI)
     Men
      Localized 93.2 (92.6-93.6) 94.2 (93.4-94.9) 42.8 (41.9-43.8) 41.2 (39.9-42.6) 100.9 (100.1-101.4)
      Regional 55.5 (54.6-56.4) 79.1 (78.3-80.0) 14.3 (13.4-15.2) 24.5 (23.5-25.4) 100.8 (100.2-101.2)
      Distant 5.5 (4.9-6.1) 18.3 (17.1-19.5) 2.3 (1.8-2.8) 3.9 (3.5-4.3) 59.6 (51.8-66.7)
      Unknown 51.3 (50.0-52.6) 66.8 (65.2-68.4) 22.9 (21.9-24.0) 13.4 (12.5-14.4) 98.1 (96.6-99.2)
     Women
      Localized 91.0 (90.3-91.6) 91.1 (90.2-91.9) 42.5 (41.0-44.1) 57.9 (55.8-59.9) 100.3 (100.2-100.5)
      Regional 56.1 (54.8-57.3) 76.3 (75.4-77.3) 15.1 (13.5-16.8) 36.5 (34.6-38.4) 99.9 (99.8-100.1)
      Distant 5.5 (4.7-6.4) 18.3 (17.0-19.6) 3.4 (2.5-4.4) 7.0 (6.3-7.8) 72.5 (68.2-76.3)
      Unknown 45.4 (43.8-47.0) 58.3 (56.5-60.1) 21.0 (19.5-22.7) 21.4 (19.7-23.1) 98.7 (98.3-99.1)
    Primary Site Stage at diagnosis
    Localized
    		 Regional
    		 Distant
    		 Unknown
    No. 5-RSR (SE) No. 5-RSR (SE) No. 5-RSR (SE) No. 5-RSR (SE)
    Stomach
     20-49 yr 12,299 97.2 (0.2) 6,745 65.9 (0.7) 3,500 4.9 (0.5) 1,816 67.5 (1.2)
     50-64 yr 26,315 96.7 (0.2) 11,720 62.2 (0.6) 5,102 7.6 (0.5) 3,842 64.9 (0.9)
     65-74 yr 20,690 92.2 (0.4) 10,343 53.4 (0.7) 4,493 5.3 (0.5) 4,266 52.8 (1.0)
     ≥75 yr 8,885 71.2 (1.1) 5,659 31.8 (1.1) 3,057 3.1 (0.5) 4,808 22.8 (0.9)
    Colorectum
     20-49 yr 5,761 97.8 (0.3) 5,933 82.1 (0.7) 2,366 22.9 (1.2) 1,475 81.7 (1.2)
     50-64 yr 14,546 97.4 (0.3) 15,509 83.2 (0.5) 5,203 22.1 (0.8) 3,391 78.5 (0.9)
     65-74 yr 10,936 92.2 (0.6) 13,377 77.2 (0.6) 4,551 17.6 (0.9) 3,187 63.8 (1.1)
     ≥75 yr 5,326 75.3 (1.4) 7,234 63.5 (1.2) 3,117 8.8 (0.9) 3,074 33.7 (1.3)
    Liver
     20-49 yr 5,766 50.7 (0.9) 3,277 16.5 (0.9) 2,037 2.6 (0.5) 2,261 29.9 (1.1)
     50-64 yr 13,942 48.9 (0.6) 6,642 16.5 (0.7) 3,812 3.1 (0.4) 5,420 29.3 (0.7)
     65-74 yr 7,914 35.3 (0.8) 4,044 11.8 (0.8) 2,508 2.0 (0.4) 3,852 18.0 (0.8)
     ≥75 yr 3,442 17.7 (1.2) 2,006 9.2 (1.1) 1,499 1.6 (0.6) 2,848 6.8 (0.8)
    Lung
     20-49 yr 1,006 76.6 (1.8) 1,228 48.0 (1.9) 2,666 8.9 (0.8) 599 30.7 (2.3)
     50-64 yr 4,444 64.4 (0.9) 6,551 37.3 (0.8) 9,640 6.8 (0.4) 2,528 25.6 (1.0)
     65-74 yr 5,794 41.4 (1.0) 8,296 24.0 (0.7) 12,432 3.8 (0.3) 4,617 15.1 (0.7)
     ≥75 yr 3,723 20.5 (1.2) 4,854 12.4 (0.8) 8,487 2.6 (0.3) 5,077 8.8 (0.6)
    Female breast
     20-49 yr 16,882 97.8 (0.2) 11,734 90.7 (0.4) 1,354 34.9 (2.0) 3,100 92.7 (0.5)
     50-64 yr 10,790 97.8 (0.3) 6,957 89.1 (0.6) 863 32.4 (2.4) 2,007 90.3 (0.8)
     65-74 yr 2,898 96.6 (0.9) 1,734 83.9 (1.6) 291 25.8 (3.8) 592 83.5 (2.1)
     ≥75 yr 803 93.1 (3.0) 503 70.3 (4.1) 125 16.7 (5.9) 331 51.7 (4.4)
    Cervix uteri
     20-49 yr 5,567 95.3 (0.4) 1,772 71.6 (1.4) 354 30.3 (3.1) 897 89.6 (1.1)
     50-64 yr 2,787 90.9 (0.8) 1,567 77.4 (1.5) 339 34.2 (3.6) 599 78.0 (1.9)
     65-74 yr 1,415 85.9 (1.5) 823 68.8 (2.2) 187 20.0 (3.6) 395 70.2 (2.9)
     ≥75 yr 616 63.2 (3.5) 471 48.6 (4.1) 236 9.4 (3.8) 383 36.3 (3.6)
    Prostate
     20-49 yr 209 94.6 (2.9) 65 84.1 (7.1) 45 26.6 (10.1) 55 86.7 (5.0)
     50-64 yr 3,982 99.5 (0.6) 1,595 94.7 (1.3) 515 37.6 (3.3) 877 93.7 (1.3)
     65-74 yr 7,723 100.9 (0.7) 2,781 97.1 (1.4) 1,185 39.1 (2.3) 2,132 90.0 (1.4)
     ≥75 yr 3,942 95.3 (1.9) 1,108 88.8 (3.7) 888 32.6 (3.1) 2,079 81.4 (2.4)
    Thyroid
     20-49 yr 31,637 100.2 (0.1) 34,842 100.3 (0.0) 450 95.9 (1.3) 7,199 100.0 (0.1)
     50-64 yr 18,110 100.7 (0.1) 18,223 100.6 (0.1) 341 74.6 (3.4) 4,406 99.7 (0.3)
     65-74 yr 3,760 101.2 (0.6) 4,078 97.6 (0.8) 279 45.8 (4.4) 1,068 96.5 (1.3)
     ≥75 yr 571 99.4 (3.2) 684 88.8 (3.7) 177 24.5 (5.5) 390 65.1 (4.6)
    Primary site Stage
    at diagnosis    		 Korea (2006-2010)
    		 US (2002-2008)a)
    Stage
    distribution (%)    		 5-year
    RSR (%)    		 Stage
    distribution (%)    		 5-year
    RSR (%)
    Stomach Localized 51 92.4 24 62.3
    Regional 26 55.7 31 27.7
    Distant 12 5.5 34 3.7
    Unknown 11 49.2 11 17.9
    All stages 100 67.0 100 26.9
    Colorectum Localized 35 93.0 39 89.9
    Regional 40 78.0 36 69.6
    Distant 15 18.3 20 11.9
    Unknown 11 63.2 5 33.9
    All stages 100 72.7 100 64.3
    Liver Localized 44 42.8 40 27.9
    Regional 22 14.5 26 9.8
    Distant 14 2.5 19 2.2
    Unknown 20 22.4 15 5.9
    All stages 100 26.7 100 15.2
    Lung Localized 18 46.3 15 52.2
    Regional 26 27.2 22 25.1
    Distant 41 4.8 56 3.7
    Unknown 16 15.7 6 7.9
    All stages 100 19.7 100 15.9
    Breast Localized 52 97.6 60 98.4
    Regional 34 89.2 33 83.9
    Distant 4 32.2 5 23.8
    Unknown 10 89.1 2 50.7
    All stages 100 91.0 100 89.0
    Cervix Localized 56 91.1 47 90.7
    Regional 25 70.9 36 56.7
    Distant 6 25.8 12 16.2
    Unknown 12 75.1 4 54.8
    All stages 100 80.2 100 67.9
    Prostate Localized 54 99.2 82 100.0b)
    Regional 19 94.7 11 100.0b)
    Distant 9 36.4 4 28.8
    Unknown 18 87.9 3 71.1
    All stages 100 90.2 100 99.2
    Thyroid Localized 43 100.4 68 99.9
    Regional 46 100.1 25 97.1
    Distant 1 69.1 5 53.9
    Unknown 10 98.6 2 87.4
    All stages 100 99.8 100 97.5
    Table 1 Basic characteristics of cancer patients

    Table 2 Five-year relative survival rates and 95% confidence intervals (CIs) for selected cancer sites

    Table 3 Stage distribution and 5-year relative survival rates with 95% confidence intervals (CIs) for selected cancer sites by sex

    Table 4 Number of patients and 5-year relative survival rates (RSRs) of selected cancer sites by age and stage at diagnosis

    Values are presented as number of cases (%). SE, standard error.

    Table 5 Comparison of 5-year relative survival rates (RSRs) for selected cancers in Korea and the US by stage at diagnosis

    a)Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2009.

    Bethesda: National Cancer Institute; 2012 [21], b)Survival truncated if greater than 1.0 (100%).

    Table 1

    Table 2

    Table 3

    Table 4

    Table 5

    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP